To: Tor Van Dyke who wrote (62 ) 4/16/1998 9:31:00 PM From: Clay Degenhardt Read Replies (1) | Respond to
Tor- good post. I should give Mr. Steinke (Pres.) a call and ask what he's up to. Last year, I was lead to believe that the purchase of new equipment at that time was all that was needed to satisfy manufacturing requirements. Especially if they have no income, what's happening with the manufacturing resources currently in place? If the money is for COGS, they should be able to easily get a loan and repay it as inventory is sold. Also, they used to have a contract for bicycle tires and several other specialized-tire deals (shopping carts, wheelchairs, etc). The high percentage of outstanding shares owned by management should give them plenty of incentive to make their business flourish, but the downside is that there is not a lot of outside pressure for them to produce. I see lack of debt as primarily good: Less likelihood of going bust because of creditors (very good for us). I would REALLY like to talk to Chrobak: He is the chief technical guy who left last year under strange circumstances and was the one who refined the products for which their patents are based. If I were him, I certainly would want a piece of the success if my inventions were to eventually payoff. I think the Cooper deal would have come to fruition by now if there was anything substantial there. no apology required to me on the "everything on track" comment... I wasn't quite sure where the tracks were! Someone blew-out a bunch of shares today. Maybe an insider had to make a house payment for the month since there's no income... A well-respected board member joined last year and it was speculated he would be able to provide a number of contacts for establishing deals. Can't recall his name, but the stock really reacted well to that. Since there's been no news, I have no idea what effect he has had since joining. I guess the past experience with Goodyear didn't stick in my mind; what I do recall is the extensive past experience with UTI Chemical which was probably what led to ATYR buying the money-losing European UTI office last year (I wonder what's happening with that too?).
